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Abstract: Microorganisms, including pathogenic or opportunistic bacteria and fungi, may gain access
to the uterus during breeding, and infectious endometritis plays a major role in equine subfertility.
This study aimed to assess the post-breeding inflammatory response, endometrial culture, and
embryo recovery of mares susceptible to persistent breeding-induced endometritis (PBIE) treated
with plasma-rich (PRP) or -poor (PPP) plasma. Mares (n = 12) susceptible to PBIE had three cycles
randomly assigned to receive intrauterine infusions of lactate ringer solution (LRS, control), or
autologous PRP or PPP pre- (−48 and −24 h) and post-breeding (6 and 24 h). Mares were bred with
fresh semen from one stallion. Intrauterine fluid accumulation (IUF) and endometrial neutrophils
were assessed every 24 h up to 96 h post-breeding. Uterine cytokines (Ilβ, IL6, CXCL8, and IL10)
were evaluated before (0 h), 6, and 24 h post-breeding, and endometrial culture three and nine
days after breed. Embryo flushing was performed 8 days post-ovulation. Data were analyzed with
mixed model, Tukey’s post-hoc test, and multivariate regression. PRP treatment reduced endometrial
neutrophils, post-breeding IUF, and pro-inflammatory cytokines when compared to control-assigned
cycles, but not significantly different than PPP. Controls had a significantly higher percentage of
positive bacterial cultures (33%) in comparison to PRP-assigned cycles (0%), whereas cycles treated
with PPP were not significantly different from the other groups (25%). The PRP-assigned cycles had
significantly greater embryo recovery rates (83%) than the control (33%), though not significantly
different than PPP (60%). Plasma infusion reduced the duration and intensity of the post-breeding
inflammatory response and improved embryo recovery in mares susceptible to PBIE. Platelets
incrementally downregulate PBIE and appear to have a dose-dependent antimicrobial property.
Keywords: endometrium; uterine inflammation; equine; PRP; immunomodulation
1. Introduction
Endometritis is the third most common disease affecting horses in the United States [1]
and is the number one cause of subfertility and poor reproductive efficiency in mares [2].
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Mares are classified as susceptible or as resistant to endometritis based on their ability to
clear uterine infection/inflammation by 48–72 h post-breeding [3]. Persistent breeding-
induced endometritis (PBIE) can be caused by infectious (i.e., bacteria and fungus) and by
non-infections agents such as sperm [4]. All mares display a physiological and transient
uterine inflammatory response; however, the mares deemed susceptible to PBIE have a
delayed and prolonged uterine inflammatory response [5]. The persistent endometrial
inflammation leads to a hostile uterine environment for the embryo entering the uterus,
compromising embryo recovery and pregnancy rates [6,7].
Infectious endometritis plays a major role in equine subfertility; up to 25–60% of
mares failing to become pregnant have bacterial uterine infection [8–11]. Microorganisms,
including pathogenic or opportunistic bacteria and fungi, may gain access to the uterus
during breeding. While the resistant mares respond rapidly to the presence of sperm and
microorganisms, inadequate immune response may lead to persistent inflammation and
infection in mares susceptible to PBIE [12].
Traditionally, PBIE has been treated with multi-modal therapeutics, such as a com-
bination of uterine lavage, ecbolic agents, anti-inflammatories, and antibiotics [8]. While
employing multi-modal therapeutics effectively manages PBIE, some mares, particularly
aging broodmares and donor mares enrolled in embryo transfer programs for multiple
years, often fail to respond to traditional therapy for PBIE (8). Furthermore, in numerous
stud farms, all mares in the premises are prophylactically infused with broad-spectrum
antibiotics regardless of need; such practice likely contributes to the development of an-
timicrobial resistance.
In recent years, the lack of response to conventional therapy coupled with the in-
creasing incidence of antibiotic-resistant bacteria led to the development of alternative
treatments for mares suffering from PBIE [13]; these have been largely attributed in part to
the indiscriminate use of antibiotics in veterinary medicine (e.g., non-select intrauterine
infusion in mares). Multidrug-resistant microorganisms pose a major global threat to public
health. Autologous platelet-rich plasma (PRP), a whole blood plasma with a high platelet
concentration, is becoming a popular nontraditional therapy in human and veterinary
medicine as an alternative to circumvent such problems. This byproduct has been used for
its anti-inflammatory, regenerative, and antimicrobial properties [14–18].
Platelets, or thrombocytes, are fragments of cytoplasm derived from megakaryocytes,
which are large cells present in the bone marrow [19]. The cytoplasm of platelets is
subdivided into chromomere, where granules accumulate, and the hyalomere, an agranular
region rich in cytoskeletal proteins [15]. Platelet granules contain numerous proteins such
as fibrinogen, growth factors (e.g., transforming growth factor β, vascular endothelial
growth factor), cytokines (e.g., CXCL8 and TNFα), and antimicrobial peptides (e.g., platelet
factor 4, RANTES, connective tissue activating peptide 3, platelet basic protein, thymosin
beta-4, fibrinopeptide A and B) [20,21].
In mare reproductive practice, studies showed that intrauterine infusion with PRP could
improve pregnancy rates by mitigating the post-breeding inflammatory response [22–26],
but PRP has not been critically assessed in embryo donors mares, a group of mares prone
to PBIE. Platelets’ natural antimicrobial peptides are thought to be responsible for PRP’s
benefit on septic arthritis in horses [27]; however, PRP’s anti-microbial beneficial properties
have yet to be evaluated in mares susceptible to PBIE.
The hypotheses of this study are that the administration of PRP to embryo donor mares
susceptible to PBIE will result in fewer uterine infections and a lessened post-breeding
inflammatory response in comparison with platelet-poor-plasma (PPP) or control (Lactate
Ringer’s Solution LRS) treatments. Specifically, PRP therapy reduces the duration and inten-
sity of the post-breeding inflammatory response and reduce the chances of post-breeding
uterine infection leading to enhanced embryo recovery rates of mares susceptible to PBIE.
This study aimed to compare PRP and PPP’s effects with control-assigned cycles on uterine
microbiology, endometrial inflammation, intrauterine fluid accumulation, progesterone
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concentration, and endometrial receptor expression and embryo recovery rates in mares
susceptible to PBIE.
2. Results
2.1. Screening Mares for Susceptibility to PBIE
After screening twenty-two mares, twelve mares were identified as susceptible and
seven as resistant to PBIE [3], while three were deemed intermediate. Susceptible mares
had an increased intrauterine fluid until 72 h post-sperm challenge (p < 0.05), while resistant
mares did not (p > 0.05) (Supplementary Figure S1). In addition, susceptible mares had
greater intrauterine fluid accumulation than resistant mares at all time points post-sperm
challenge (p < 0.05). Similarly, PMNs were more abundant post sperm-challenge (p < 0.05)
in susceptible mares than resistant mares (Figure 1). There was an effect of time (p < 0.05)
but no differences between mare groups for edema scores (p > 0.05) (Supplementary
Figure S2). Eight mares were classified as IIB and four mares as III in the susceptible group,
whereas in the resistant mares, two were classified as I and five were classified as IIA.
Figure 1. Representative density plot for flow cytometric analyses performed on platelet-rich (A)
and -poor (B) plasma obtained from a mare susceptible to persistent-breeding induced endometritis.
Platelets were identified with a primary (mouse monoclonal antibody anti CD41/61) and secondary
antibody anti-mouse IgG conjugated with a fluorochrome (PE, R-phycoerythrin, X-axis) and their
membrane integrity was assessed with Zombie Green (Y-axis). The right quadrants enclosed CD41/61
positive events, presumptively corresponding to platelets, with high (damaged membrane) or low
(intact membrane) Zombie Green signal. The left quadrants included CD41/61 negative events, likely
debris, with high or low Zombie Green signal.
2.2. Platelet-Rich or -Poor Plasma
Mares susceptible to PBIE had a platelet concentration in whole blood ranging from
74.6 to 188.0 × 103 platelets per µL (Table 1). There was a moderate correlation (r = 0.5)
between the platelet concentration in the whole blood and the PRP’s final platelet con-
centration. The mean platelet concentration increased 5.2-fold in PRP compared to the
whole blood count (p = 0.0003, Table 1). There was a reduction in RBC (266-fold) and
WBC (248.5-fold) in PRP and PPP in comparison to whole blood (p < 0.0001). Platelet-poor
plasma had a lower platelet concentration than the whole blood (3.3-fold reduction) and
PRP (17.3-fold reduction) (p < 0.02, Table 1). Platelet viability was similar for both PRP
(97.0 ± 0.7%) and PPP (97.2 ± 0.6%) (p = 0.79, Figure 1). The mean number of platelets
infused in the uterus of mares was greater in PRP (24.9 ± 1.2 × 109 platelets) than PPP
(1.4 ± 0.2 × 109 platelets) (p < 0.001).
2.3. Semen Parameters
Twenty-six ejaculates were harvested and used for breeding in the study. Breeding
doses and sperm parameters did not differ across cycles during the experiment (p > 0.05,
Table S1).
Antibiotics 2021, 10, 490 4 of 19
2.4. Intrauterine Fluid Accumulation and Endometrial Edema
There were no differences for intrauterine fluid accumulation before treatment (−48 h)
and breeding (0 h) in all cycles (p > 0.05, Figure 2A). Endometrial edema scores were not
different among groups at 0, 24, 48, 72, and 96 h (p > 0.05). However, intrauterine fluid
accumulation was reduced up to 96 h post-breeding in mares with assigned cycles to receive
PRP when compared to mares assigned to the control cycles (p < 0.05). The cycles assigned to
PPP were not different than PRP or control-assigned cycles (p > 0.05) (Figure 2A). However,
at 48 h, intrauterine fluid accumulation tended (p = 0.09) to be reduced in the PPP assigned
cycles when compared to the control cycles. At 96 h after breeding, mares in the control
cycle had more intrauterine fluid accumulation than mares treated with PRP (p = 0.043).
Two mares stopped cycling due to seasonality while assigned to PPP cycles; therefore, only
ten cycles were fully completed for PPP.
Figure 2. Post-breeding inflammatory response in mares susceptible to persistent breeding induced
endometritis. Assessments were carried out from pre- (early onset of estrus) and post-breeding, and
on the day of embryo flushing (eight days post-ovulation, D8): (A) Intrauterine fluid accumulation
pre- and post-breeding; (B) mean polymorphonuclear cells (PMNs) assessed in five high-power
fields (hpf) in endometrial cytology, and (C) mean PMNs counts assessed in five hpf in endometrial
biopsies. Mares (n = 12) had estrous cycles (n = 34) assigned to receive four intrauterine infusions
with Lactate Ringer’s Solution (Control, n = 12), platelet-rich (PRP n = 12), or -poor plasma (PPP n
= 10) in a crossover design. Different superscripts denote the effects of time (a,b,c) and differences
between groups (X,Y) (p < 0.05). Asterisk (*) denotes tendency (0.05 < p < 0.1).
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Table 1. Platelets, red blood cells (RBC) and white blood cells (WBC) in the whole blood (WB), platelet-
rich (PRP), and platelet-poor (PPP) plasma obtained from 96 venipunctures from mares susceptible
to persistent breeding-induced endometritis. Each mare cycle was assigned in a crossover-designed
to either PRP (n = 12), PPP (n = 10), or control (n = 12) group.
WB PRP PPP
Platelets (103/µL) 119.9 ± 30 b 622.9 ± 144 a 36.0 ± 25 c
RBC (106/µL) 6.4 ± 0.9 a 0.02 ± 0.022 b 0.01 ± 0.011 b
WBC (103/µL) 5.6 ± 1.2 a <0.001 b <0.001 b
Mean ± SEM. Different superscripts (a,b,c) denote differences among columns within rows (p < 0.05).
2.5. Inflammatory Cell Counts on Endometrial Biopsy and Cytology
Endometrial cytology revealed that PRP reduced (p < 0.0001) the PMNs number at 24
and 72 h, as well as tended (p = 0.08) to reduce at 48 h after breeding when compared with
similar time points in the control-assigned cycles (Figure 2B). The PPP-assigned cycles did
not differ from the other cycle-assignments for the number of PMNs in cytology (p > 0.05).
However, both PRP and PPP reduced the number of PMNs in endometrial biopsies at 6
(p = 0.001) and 24 h (p < 0.0001) post-breeding and eight days post-ovulation (p = 0.0047,
Figures 2C and 3). There were no differences in the number of lymphocytes among groups
or time points (p > 0.05; Figure 3). Moderate correlation (r = 0.65) was observed between
PMNs counted in endometrial cytology samples and endometrial biopsy samples.
Figure 3. Representative images of H&E-stained endometrial biopsies collected from mares suscepti-
ble to persistent breeding-induced endometritis pre- (−48 h) and post-breeding (6 and 24 h), and on
the day of embryo flushing (eight days post-ovulation, D8). Mares were treated with four intrauterine
infusions of Lactated-Ringer’s solution (Control), platelet-rich (PRP), or -poor plasma (PPP). White
arrows indicate neutrophils and black arrows indicate lymphocytes. Magnification ×400.
2.6. Cytokine Concentrations in Uterine Fluid
Cytokine concentrations were assessed in a subset of mares. There were no changes
in the concentration of the cytokines assessed in the present study among cycles before
breeding (p > 0.05). Concentrations of IL1β increased 6 h post breed in all groups (p < 0.05,
Figure 4A), and cycles treated with PRP had lower IL1β and IL6 at 24 h than control-
assigned cycles (p < 0.05, Figure 4A, B). CXCL8 increased post-breeding in mares at the
control-assigned cycle (p < 0.05, Figure 4C). Greater concentrations of CXCL8 were noted
post-breeding (6 and 24 h) in mares assigned to control cycles compared with PRP-assigned
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cycle (p < 0.05, Figure 4C). There were no changes in IL10 concentrations in the uterine
fluid across time or treatment (p > 0.05, Figure 4D).
Figure 4. Concentrations (log10) of cytokines ((A), IL1β; (B), IL6; (C), CXCL8; (D), IL10), in uterine
fluid of mares susceptible to persistent breeding induced endometritis. Assessments were carried
out from pre- (0 h, early onset of estrus), 6, and 24 h post-breeding. Mares (n = 6) had estrous cycles
(n = 18) assigned to receive four intrauterine infusions with Lactate Ringer’s Solution (Control, n = 6),
platelet-rich (PRP n = 6), or -poor plasma (PPP n = 6) in a crossover design. Different superscripts
denote the effects of time (a,b,c). Asterisk (*) denotes difference between control- and PRP-assigned
cycles (p < 0.05).
2.7. Immunohistochemical Evaluation
Positive nuclei to PR were brown-stained, while negative nuclei were blue-stained
by hematoxylin counterstain. The PR expression was intensely detected in epithelial cells
and glandular epithelium; however, it was rarely detected in the stroma. There were
no changes in PR expression between treatments (p > 0.05; Figure 5). Negative controls
showed no immunoreaction.
Figure 5. Representative images of immunohistochemical PR expression in uterine biopsies (200×
magnification) from mares susceptible to persistent breeding-induced endometritis pre-breeding
(−48 h) and on the day of embryo flushing (eight days post-ovulation, D8). Mares were treated
with four intrauterine infusions of Lactated-Ringer’s solution (Control), platelet-rich (PRP), or -poor
plasma (PPP). Positive nuclei to PR were brown-stained, while negative nuclei were blue stained by
hematoxylin counterstain.
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2.8. Endometrial Culture and Progesterone Concentrations
Estrous cycles assigned as Control and PPP tended (p = 0.08) to result in a greater
percentage of positive aerobic bacterial cultures at Day-2 than PRP cycles. In contrast, at
Day-8, mares assigned as control had a greater percentage of positive bacterial cultures in
comparison to PRP-assigned cycles (0%) (p = 0.0373), whereas cycles assigned to PPP were
not different from the other groups (p > 0.05, Table 2). The concentrations of progesterone
increased over time across groups (p < 0.0001), and PRP assigned cycles had greater
progesterone concentrations at Day-8 than in the control-assigned cycles (p = 0.0376), but
not different than PPP assigned-cycles (p > 0.05; Figure 6). There were no differences on
progesterone concentrations between mares with positive and negative embryo flushes
in the control group (p > 0.05) or all cycles together positive vs. negative embryo flushing
(p > 0.05; Figure S3).
Table 2. Aerobic culture results of aerobic obtained Day 2 (D2) and Day 8 (D8) post-ovulation in mares susceptible to
persistent breeding-induced endometritis. Estrous cycles (n = 34) from twelve mares were assigned in a crossover design to
receive intrauterine uterine infusions with Lactated Ringer’s Solution (Control, n = 12), platelet-rich (PRP, n = 12) or -poor
plasma (PPP, n = 10).
D2 D8
Mare ID Control PRP PPP Control PRP PPP
1 - - - - - -
2 - - Enterococcus spp. - - -
3 Streptococcus β-hemolytic - - Streptococcus β-hemolytic - -
4 - - - - - Klebsiella pneumoniae
5 Klebsiella pneumoniae - - Klebsiella pneumoniae - -
6 - - - - - -
7 Streptococcus β-hemolytic - Streptococcus β-hemolytic - - -
8 - - - Escherichia coli - -
9 - - Streptococcus β-hemolytic Escherichia coli - Streptococcus β-hemolytic
10 - - NP - - NP
11 - - NP Escherichia coli - NP
12 - - - - - -
NP, not performed.
Figure 6. Circulating progesterone concentrations pre- and post-ovulation in mares susceptible to
persistent breeding induced endometritis. Mares (n = 12) had estrous cycles (n = 34) assigned to
receive intrauterine infusions with Lactate Ringer’s Solution (LRS) (Control, n = 12), platelet-rich
(PRP n = 12), or -poor plasma (PPP n = 10) in a crossover design. Assessments were carried out from
the early onset of estrus (D-3), 48 h post-ovulation (D2) and on the day of embryo flushing, eight days
post-ovulation (D8): Different superscripts denote the effects of time (a,b,c) and differences between
groups (X,Y) (p < 0.05).
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2.9. Embryo Recovery Rates
Embryo recovery was greater in PRP-assigned cycles (83%) when compared with
control-assigned cycles (33%) (p = 0.0361), whereas PPP-assigned cycles had intermediate
embryo recovery rates but not different from the other assigned cycles (p > 0.05). Of interest,
when treatment was considered as an independent variable (PRP and PPP), mares had
greater fertility rates after plasma therapy (p = 0.0356; 72%, 16/22) than the control-assigned
group. The PRP and PPP treatments increased 2.5- and 1.5-fold the embryo recovery rates
compared with the control assigned cycles. In addition, when data were adjusted for the
number of ovulations per cycle, PRP therapy increased embryo recovery (73.3%) compared
with the control cycle (28.6%) (p = 0.0268). In the PPP assigned cycles, the embryo recovery
rate was intermediate (53.9%), when embryo recovery rates were adjusted for the number
of ovulations per cycle but not different than other cycles-groups (p > 0.05).
A total of 20 successful embryo collections were attained. Four embryos were re-
covered from four mares in the control-assigned cycles, with two of these mares having
double ovulations. Eleven embryos were recovered in PRP-assigned cycles, and seven
embryos were recovered from the PPP-assigned cycles. Three mares experienced double
ovulations in both plasma-assigned cycles. The overall grade quality, stage of development,
and diameter of embryos collected were similar across cycle assignments (p > 0.05, Table 3).
Table 3. Embryos obtained from mares susceptible to persistent breeding-induced endometritis. Estrous cycles (n = 34)
from twelve mares were assigned in a crossover design to receive intrauterine uterine infusions with Lactated Ringer’s
Solution (Control, n = 12), platelet-rich (PRP, n = 12) or -poor plasma (PPP, n = 10). Embryo flushing was performed eight
days after ovulation, with 4 L of LRS. All embryos recovered were measured and graded for development (e.g., blastocyst,
or expanded blastocyst) and quality [28].
Control PRP PPP
Mare ID Embryo STAGE QualityGrade
Diameter







1 - - Blastocyst 1 340 Blastocyst 1 260
Expanded blastocyst 1 1100
2 - - - - - -
3 - - Expanded blastocyst 1 1230 Early blastocyst 1 175
4 Expanded blastocyst 1 540 Expanded blastocyst 1 860 Expanded blastocyst 1 840
5 - - - - - -
6 Early blastocyst 2 195 Expanded blastocyst 1 1360 - -
7 Blastocyst 1 960 Early blastocyst 2 190 Expanded blastocyst 1 940
8 - - Blastocyst 1 340 Expanded blastocyst 1 650
9 - - Blastocyst 1 300 - -
10 - - Blastocyst 1 360 NP NP
11 - - Early blastocyst 1 165 NP NP
12 Blastocyst 1 360 Blastocyst 1 280 Blastocyst 1 320
Blastocyst 1 360
Grade 1 embryo with a spherical shape, uniform size of blastomeres, color, and texture, with no visible abnormalities. Grade 2 embryo
with slight irregularities in shape, size of blastomeres, color or texture, and can present some extruded blastomeres. Grade 3 embryo can
have a large percentage of extruded blastomeres, partial collapse of blastocele, or moderate shrinkage of trophoblast from zona pellucida.
Grade 4 degenerated embryo with variable advanced stages irregularities. [28]. NP, not performed.
3. Discussion
The present study was set forth to assess blood plasma therapy (rich or poor in
platelets) in embryo donor mares susceptible to PBIE. Intrauterine treatment with plasma
mitigated PBIE in susceptible mares as evidenced by the reduction of intraluminal and
endometrial PMNs, uterine inflammatory cytokines, intrauterine fluid accumulation, and
the number of positive bacterial cultures compared to control-assigned cycles. Ultimately,
intrauterine PRP therapy increased the percentage of embryo recovered per flushing
and per number of ovulations, likely due to its immunomodulatory and antimicrobial
properties of platelets turning a hostile uterine environment into an embryo-friendly
uterine environment in embryo donor mares susceptible to PBIE.
It is unclear how PRP’s infusions improve endometrial receptivity and fertility in
mares. In humans, it has been shown that PRP enhances migration and proliferation of en-
dometrial cells [29], promotes neo-angiogenesis in the endometrium of infertile women [30],
and upregulates genes involved in implantation (e.g., prostaglandin-endoperoxide syn-
Antibiotics 2021, 10, 490 9 of 19
thase 2 [COX2], tumor protein p53 [TP53], estrogen receptors [ER-α and ER-ß] and proges-
terone receptor) [31]. It is possible that the antimicrobial and anti-inflammatory properties
of PRP may act synergistically to improve the uterine environment.
Platelet-rich plasma is routinely used in equine clinical practice to treat joints, bursae,
and soft tissue injuries (e.g., tendonitis, tenosynovitis, and skin wounds) [32–34]. Interesting
recent findings demonstrated potent in vivo antimicrobial properties against bacterial
growth in equine synovial fluid [17] and in infected skin wounds of dogs [16]. In mare
reproductive practice, autologous PRP administration before breeding to barren mares
susceptible to endometritis improved pregnancy rates [24,25]. In addition, PRP was
shown to downregulate endometrial transcripts for interleukins IL1β, IL6, and CXCL8 and
consequently mitigated post-breeding inflammatory response [23,25]. In addition, other
therapies used to mitigate PBIE (e.g., administration of dexamethasone or Mycobacterium
phlei cell wall extract) also reduce the endometrial expression of pro-inflammatory cytokines
(e.g., IL1 and IL6) [35,36]. Our findings herein with embryo donor mares corroborate with
these previous studies with broodmares, highlighting PRP’s benefits for uterine immunity
and reproductive performance. However, the mechanisms of action of PRP in the uterus
remain to be fully elucidated. It is not well known if this downregulation in inflammatory
markers post-breeding in mares treated with PRP is due to the anti-inflammatory or the
antimicrobial properties of PRP, since bacterial uterine infection upregulates inflammatory
cytokines in mares [36–39].
Studies in other body systems (i.e., human chondrocytes) suggested that PRP acts by
inhibiting the translocation of nuclear factor-kappa B (NF-kB) to the nucleus [40,41], as hep-
atocyte growth factor contained in PRP prevents the migration of NF-kB from the cytosol to
the nucleus [40]. The downstream effects of NF-kB include activation of pro-inflammatory
cytokines, chemokines, and COX-2 that regulate the inflammatory signals [42]. Cytokines
and COX-2 act as mediators between cells modulating the acute inflammatory response [43].
Notably, PRP was shown to suppress COX-2 in the endometrium of mares susceptible to
PBIE [25].
Mares susceptible to PBIE have pronounced expression of pro-inflammatory and
reduced anti-inflammatory cytokines to regulate acute inflammation when compared to
resistant mares [35,44]. IL10 is an anti-inflammatory cytokine able to reduce the tran-
scription of pro-inflammatory cytokines by inflammatory cells [45]. Despite the lack of
change in luminal IL10 in the present study, intrauterine infusion of PRP downregulated
the pro-inflammatory cytokines (e.g., IL1β, IL6, and CXCL8), which might prevent uncon-
trolled inflammatory response. Specifically, the endometrial mRNA abundance of IL1β,
IL6, CXCL8, and TNFα are higher in susceptible than resistant mares, even before contact
with the antigen [35], therefore justifying the strategy used herein to start treating mares
before breeding, but it remains to be determined if treating mares with PRP both before and
post-breeding have additional immunomodulatory benefits than treating mares only pre-
or post-breeding. Infusion of PRP pre- or post-breeding was reported to result in similar
downregulation of the post-breeding inflammatory response in mares [25].
The chemoattraction of PMNs is mainly mediated by CXCL8 [44,46]. One study
demonstrated a reduction in transcripts for endometrial CXCL8 in PRP-treated mares [23].
In the present study, a reduction in luminal CXCL8 concentration at 6 and 24 h post-
breeding was also observed in mares treated with PRP; this can explain the suppression of
inflammatory cells observed in the present study. Future studies should be carried out to
determine the mechanistic interactions between the endometrium of mares susceptible to
PBIE and plasma and platelets.
Intrauterine infusion of bacteria upregulates inflammatory cytokines in mares [36–39].
Pathogenic microorganisms may gain access to the uterus during breeding, and the con-
tamination of the uterus with bacteria increases the inflammatory reaction and delays
the healing process by causing ongoing inflammation [8,36,38]. Of interest, none of the
PRP-assigned cycles had a positive bacterial culture at two- and eight-days post-ovulation,
whereas 25% and 42% control-assigned cycles had positive bacterial cultures two days
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post-ovulation and on the day of embryo flushing, respectively. On the other hand, the
PPP-assigned cycles, which had 17 times fewer platelets than PRP, had three (30%) es-
trous cycles with a positive aerobic culture two- and eight-days post-ovulation. Platelets
contain Growth factors and antimicrobial peptides [47,48], which may be responsible for
the findings of the present study. Peptides in platelets may explain the dose-dependent
antimicrobial activity obtained here and in another study using horse’ synovial fluids as a
model [17]. The peptides contained in PRP have antimicrobial activity against Staphylo-
coccus aureus, Escherichia coli, and Klebsiella pneumoniae [18,49,50], which are known causes
of endometritis in mares [8]. While platelet-derived antimicrobial peptides have not been
described in horses, it is reasonable to suggest that horses are like to other species. In-
terestingly, an early study indicated that the addition of autologous plasma to antibiotic
therapy after breeding lactating and barren mares could improve pregnancy rates per
cycle compared with antibiotics alone [51]. Although the apparently greater concentra-
tion of platelets in PRP is correlated with increased antimicrobial potential, the plasma
components may also play an important role in antimicrobial activity of PRP [47].
Plasma contains the complement system, an element of the immune system essential
for humoral defense mechanisms against infectious agents. Bacterial cell lysis and leukocyte
recruitment are associated with the activation of the complement cascade, and apparently,
the plasma components (complement factors) play an important role for the antimicrobial
activity of platelet concentrates [47,52]. In the present study, we demonstrated that both
PRP and PPP alleviated the post-breeding endometrial inflammatory response in mares.
Our results are consistent with an in-vitro study with human endometrial cells in which
PRP and PPP had similar immunomodulatory capabilities [29]. The lack of differences
between PRP and PPP for some of the endpoints assessed in the present study could simply
mean the number of platelets contained in PPP herein was enough to elicit equivalent
immunological properties to PRP. The minimal number of platelets per infusion or the
number of infusions has not been determined yet. It is possible that after four infusions
with PPP, a minimum number of platelets was achieved in the uteri of mares susceptible to
PBIE in the present study.
Bacterial uterine infection induces endometrial inflammation [8,36]. The inflamma-
tory cascade during the peri-ovulatory period and early diestrus may induce excessive
production of PGF2α, which can negatively affect the luteal function and progesterone
concentrations, and its reduction is thought to affect pregnancy rates in mares [53]. Plasma
progesterone concentrations at Day-8 post-ovulation of mares in the control cycle were
lower than those treated with PRP or PPP. It is unknown if progesterone concentrations
were reduced in the control-assigned cycles due to chronic inflammation or due to the fact
that pregnancy rates were greater in the plasma assigned cycles. Notably, there were no
differences in progesterone concentrations between cycles with a positive and negative
embryo flushes cycles in the control group or all cycles together positive vs. negative
embryo flushes. A previous study showed that mares becoming pregnant had greater
progesterone concentrations five days post-ovulation than mares bred but not becoming
pregnant [54]. In addition, endometrial infection with pathogenic bacteria (e.g., Streptococ-
cus zooepidemicus) has been reported to decrease progesterone concentrations in the early
diestrus of mares [55]. In addition, intrauterine PRP therapy upregulated progesterone
receptors in bovine endometrial cells [31], which led the authors to suggest that intrauterine
therapy with PRP may improve cow’s fertility [31,56]. However, there were no changes
in PR expression in the endometrium of mares treated with PRP or PPP in the present
study. This could simply mean a difference between species or the small number of mares
used herein, or due to the fact that the embryos were collected eight days post ovulation, it
is possible that differences in progesterone receptor could have been seen if mares were
sampled later in diestrus/pregnancy. Thus, it remains to be determined if PRP therapy
modulates the progesterone receptor.
The assessment of post-breeding intrauterine fluid accumulation is an essential clinical
parameter associated with endometritis in mares [8]. After immune response activation,
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the pro-inflammatory cytokines, including chemokines (i.e., TNF, IL1, IL6, and CXCL8),
are released, and vascular endothelial cell activation occurs. Constriction of arterioles and
dilation of venules results from acute inflammation, which increases vascular permeability
and exudates leakage to the interstitium, causing edema and intrauterine fluid accumu-
lation [57]. Pre-breeding intrauterine fluid accumulation not associated with breeding is
indicative of susceptibility to PBIE [58]. Four mares in the present study exhibited intrauter-
ine fluid accumulation before insemination; however, all of them had negative aerobic
culture and negative endometrial cytology before each treatment. Intrauterine fluid accu-
mulation in these cases originates from endometrial gland secretion and transudation [59],
and it is usually associated with the estrus phase with increased endometrial secretion and
edema [60]. In the present study as well as previous studies, PRP therapy also showed a
reduction in the intrauterine fluid accumulation in barren mares and mares with chronic
degenerative endometritis [22,24], which suggests a beneficial effect of this therapy for
mares with delayed uterine clearance. In the present study, all mares had uterine lavage
performed at various time points for sampling. This procedure alone likely mitigated the
inflammatory response in mares. However, since mares were equally submitted to this
therapy across cycle groups, the effects of uterine lavage equally affected each cycle. It
is possible that if no uterine lavage were performed, the results could have been even
more contrasting between cycle groups. Uterine biopsy was performed across groups for
sampling purposes. It is possible that endometrial biopsy caused further inflammation;
however, since all groups were equally sampled, the effects were properly distributed
across groups.
4. Materials and Methods
All experimental protocols conducted in the present study were approved by the Insti-
tutional Animal Care and Use Committee of the University of Illinois Urbana-Champaign
under protocol # 19141. The study was carried out from May to December 2019 at the
University of Illinois Veterinary Teaching Hospital.
4.1. Screening Mares for Susceptibility to PBIE
Twenty-two light-breed mares (11.7 ± 1.2, range 5 to 18 years-old) belonging to the
University of Illinois were screened for susceptibility to PBIE as previously described [3].
All the mares were previously used as embryo donors in the principal investigator’s
research program for at least two consecutive breeding seasons.
Eight ejaculates were collected from two Quarter Horse stallions (n = 4/each) with a
Missouri artificial vagina (Nasco, Fort Atkinson, WI, USA). After collection, raw semen
was centrifuged at 600× g for 10 min, and the supernatant (seminal plasma) was discarded.
The sperm pellet was pooled, concentration was assessed, packed (Whirl-Pak, Nasco) at 2
billion sperm in 20 mL of PBS, and stored at −20 ◦C. Two freezing–thawing cycles were
performed to obtain killed sperm before each use in the screening test.
Before the screening, each mare should have no signs of pre-existent uterine infections
or inflammation as determined by endometrial aerobic bacterial culture, endometrial
cytology, and no intra-uterine fluid accumulation detected on transrectal ultrasonographic
examination. Mares had transrectal palpation and ultrasonography examination performed
every other day until a 30 mm follicle was detected. Thereafter, mares were examined
daily until the follicle reached ≥35 mm in the presence of endometrial edema score ≥ 1.
Endometrial edema was scored on each transrectal ultrasonographic examination on a
scale of 0 (absent) to 4 (max). Ovulation was induced with 500 µg of histrelin acetate
(Botupharma Sao Paulo, Brazil), and mares had 2 billion killed sperm infused into the
uterus. Endometrial cytology and ultrasound examination of the reproductive tract was
performed daily up to 96 h. Endometrial biopsy and aerobic bacterial culture samples were
obtained immediately before and 96 h after the sperm challenge. Thereafter, mares were
classified as susceptible to PBIE if they had intrauterine fluid accumulation (column ≥ 2 cm),
a positive endometrial cytology (≥3–5 PMNs/hpf), and/or a positive aerobic culture at 96
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h after sperm challenge. In addition, mares classified as susceptible to PBIE had IIB or III
scores in the Kenney and Doig classification [61].
Mares that failed to display intrauterine fluid accumulation, had negative endometrial
cytology at 48 h, and negative aerobic bacterial culture at 96 h after the sperm challenge were
deemed resistant to PBIE. To be classified as resistant to PBIE, mares also had endometrium
classified as I or IIA [61]. A mare fitting one criterion of susceptibility to PBIE but not
another was deemed as intermediate.
4.2. Experimental Design
Mares screened in the preliminary study classified as susceptible to PBIE (n = 12,
14.2 ± 0.8, range 8 to 18 years old) were enrolled. All mares were randomly assigned into
three groups in a crossover design: PRP, PPP, and LRS. After the mare had an estrous cycle
assigned in one of the groups, the mare had a washout cycle to minimize the previous
estrous cycle’s potential carryover effects. Before each treatment cycle, all mares needed to
have a negative aerobic bacterial endometrial culture, along with an endometrial cytology
free from inflammation during estrus. Otherwise, mares with positive endometrial cytology
or aerobic bacterial culture were treated as needed and had an additional washout cycle.
During each washout cycle, mares needed to fit similar criteria before being assigned in
the next treatment cycle.
For all three groups, each intrauterine infusion (four in each estrous cycle) consisted
of 40 mL of LRS, PRP, or PPP. Transrectal palpation and ultrasonography examination were
performed three times a week, and prostaglandin F2alpha (dinoprost 5 mg/animal i.m.,
Lutalyse®, Zoetis, Parsippany, NJ, USA) was administered if a CL was present to bring
mares back into estrus.
Once a preovulatory follicle was detected (≥33 mm in the presence of endometrial
edema score ≥ 1), endometrial culture, cytology, low-volume uterine lavage, and biopsy
were obtained. In addition, a plasma sample was obtained via venipuncture for assess-
ment of progesterone concentrations with an immunoassay. After sampling, mares were
submitted to uterine lavage with 2 L of LRS. Immediately after uterine lavage, mares
were enrolled in one of the three groups to receive an intrauterine infusion of 40 mL of
one of the treatments described above. Before each intrauterine procedure, the perineum
was aseptically prepared using iodine scrub, rinsed with clean water, and dried with a
paper towel. In the subsequent day, each mare received histrelin acetate (500 µg, i.m.) for
induction of ovulation followed by intrauterine treatment. On the next day, mares were
inseminated with ~2 billion of fresh semen. Six hours post-breeding, low-volume uterine
lavage and an endometrial biopsy were obtained, and the uterus was flushed with 2 L of
LRS and infused with 40 mL of one of the treatments. The next day, transrectal palpation
and ultrasonography examination, endometrial cytology, low-volume uterine lavage, and
biopsy were performed. Thereafter, the uterus was flushed with 2 L of LRS and infused
with the respective cycle-assignments.
Transrectal palpation and ultrasonography examination was performed daily to con-
firm ovulation and to assess the endometrial edema and intrauterine fluid accumulation
until three days post-ovulation. If intrauterine fluid accumulation was present, the height
and the width of the fluid column (mm2) were measured with the ultrasound caliper func-
tion at the uterine bifurcation. Oxytocin (20 units, i.m.) was administered twice daily after
each intrauterine infusion (6 and 12 h post-treatment) and then morning and afternoon 12 h
apart from 48 to 96 h post-breeding. Endometrial cytology was assessed daily until two
days after ovulation was confirmed. Mares failing to ovulate by 24 h post-insemination
had the estrous cycle discarded, submitted to a washout cycle, and re-assigned back in the
same treatment group.
Embryo flushing was performed eight days after ovulation (Day 8), with 4 L of LRS.
All embryos recovered were measured and graded for development (e.g., blastocyst or
expanded blastocyst) and quality [28]. In grade 1, the embryo had a spherical shape,
uniform size of blastomeres, color, and texture, with no visible abnormalities. A grade
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2 embryo could have slight irregularities in shape, size of blastomeres, color or texture,
and could present some extruded blastomeres. Grade 3 embryo could have a large per-
centage of extruded blastomeres, partial collapse of blastocele, or moderate shrinkage of
trophoblast from zona pellucida. Grade 4 embryo were those with varying advanced stages
of degeneration and irregularities. Immediately after embryo flushing, each mare had an
endometrial biopsy collected. Thereafter, prostaglandin F2alpha (5 mg, dinoprost, i.m.)
was administered to each mare to return to estrus.
4.3. Preparation of PRP and PPP
Immediately before intrauterine infusion of PRP or PPP, 450 mL of blood was collected
from each animal through a venipuncture of the jugular vein using an 18G needle, into a
blood transfusion bag (Jorgensen Labs, Loveland, CO, USA) containing 63 mL of citrate-
phosphate-dextrose solution with adenine as an anticoagulant. Four hundred milliliters
of whole blood were split into eight 50-mL tubes, and the samples were centrifuged at
400× g for 15 min. The supernatant was transferred into 15-mL conical tubes and again
centrifuged at 1000× g for 10 min. After the second centrifugation, 2.5 mL of plasma at
the bottom of each tube was preserved and used as PRP, while the supernatant was used
as PPP. The concentration of platelet and white and red blood cells were determined in
whole blood, PRP, and PPP samples using manual counting with a hemocytometer at the
University of Illinois Veterinary Diagnostic Laboratory.
4.4. Assessment of Platelet Viability
Platelet viability was assessed using a full-spectrum detector based (filter-less) Cytek
Aurora Flow Cytometer (Cytek Biosciences Inc., Fremont, CA, USA) adapted from protocols
published elsewhere [62,63]. Immunolabeling of CD41/61, a platelet-specific antigen,
was carried out with a primary (CD41/61, monoclonal antibody CO.35E4, #MA5-28370
Invitrogen, Life Technologies Corporation, Carlsbad, CA, USA) and a secondary antibody
conjugated with a fluorochrome (goat polyclonal anti-mouse IgG conjugated with R-
phycoerythrin; #P-852, Invitrogen, Life Technologies Corporation, OR, USA). In addition,
the association with zombie green (#423112 Biolegend, San Diego, CA, USA), a dye that
binds to cytoplasmic amines, was used to assess the plasma membrane integrity of platelets.
The working solution of Zombie Green was prepared with the dilution in PBS at a 1:100
ratio. Briefly, an aliquot of PRP or PPP was diluted 1:20 in Tyrode’s media (134 mM NaCl,
12 mM NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 mM HEPES; pH 7.4)
deprived from calcium chloride. Thereafter, the sample was incubated with Zombie Green
working solution (1:1) and anti-CD41/61 antibody (1:200) for 30 min at room temperature
in the dark.
Samples were washed (1500× g, 15 min), resuspended in Tyrode’s media, and further
incubated with goat anti-mouse IgG (1:100) for 30 min at room temperature in the dark.
Samples were washed (1500× g, 15 min), resuspended in 200 µL of the same Tyrode’s me-
dia, and immediately analyzed. This panel identified four different populations (1) intact
platelets (CD41/61+ with low zombie green intensity), (2) damaged platelets (CD41/61+
with high zombie green intensity), and (3) debris (CD41/61 negative with high or low
zombie green intensity). The analysis was concluded when at least 1,000,000 fluorescent
gated events or 150 µL of the sample were assessed. Single-stain controls and compen-
sation were used to unmix the signals. Heat-treated platelets (75 ◦C, 15 min) served as a
positive control for damaged platelets. Zombie Green and R-phycoerythrin were excited
and detected with a 488 nm and 575 nm fluorescence detector, respectively. Data were
analyzed with the software FlowJo (V10.6.2, BD Life Sciences, Franklin Lakes, NJ, USA);
the percentage of events in each population was calculated, and manual compensation was
applied as needed.
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4.5. Semen Collection and Processing
Semen from one fertile Quarter Horse stallion housed at the University of Illinois
Urbana-Champaign, IL, USA, was used for all inseminations. Semen was harvested
with a Missouri artificial vagina, with the gel-free semen fraction assessed for sperm
concentration in a Nucleocounter SP-100 (Nucleocounter SP-100, Chemometek, Lillerød,
Denmark) following the manufacturer instructions. Briefly, 50 µL of semen was diluted in
5 mL of lysis buffer (Reagent S100, ChemoMetec, Denmark) and loaded into the cassettes
before the assessment.
The sperm motility parameters were assessed using computer-assisted sperm analysis
(CASA) using default settings recommended by the manufacturer (Spermvision, Minitube
of America, Verona, WI, USA) for equine sperm. The CASA’s preset values were static
cell area 14–80 µm2; straightness threshold for progressive motility 90%; average path
velocity threshold for static cell < 9.5 µm/s; cell intensity 106; and light-emitting diode
illumination intensity 1800–2550. Each sample was incubated for 10 min at 37 ◦C before
each evaluation. A small aliquot (10 µL) of extended semen was placed on a pre-heated
slide with a coverslip for the assessments. The percentage of total percent and progressive
sperm motility was recorded for descriptive purposes. Each insemination consisted of
~2 billion sperm.
4.6. Aerobic Bacterial Culture
For aerobic endometrial cultures, the samples were obtained using double-guarded
swabs (Jorgensen Labs, Loveland, CO, USA) vaginally inserted into the uterus covered
with a sterile sleeve at pre- (48 h) and post-breeding (72 h). In addition, a sterile cotton-tip
swab was inserted in the recovered fluid obtained from the cup filter immediately after
the embryo flushing and submitted to aerobic culture. After collection, swabs were plated
in the chromogenic agar (Spectrum CS Culture System, Vetlab Supply, Inc., Palmetto Bay,
FL, USA). Plates were incubated at 37 ◦C for 48 h. Bacterial growth was identified with a
matrix-assisted laser desorption ionization time-of-flight mass spectrophotometer at the
University of Illinois Veterinary Diagnostic Laboratory.
4.7. Endometrial Cytology
Endometrial exfoliative cytology was performed pre- (48 h) and post-breeding (24,
48, and 72 h). The samples were obtained using a disposable cytobrush (Jorgensen Labs,
Loveland, CO, USA). Briefly, the cytobrush was inserted manually through the vagina
and cervix into the uterus using a sterile sleeve. After collection, the slides were prepared
and stained by Diff-Quick (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA). The
samples were then microscopically examined under 400× objective, and the number of
inflammatory cells in ten higher power fields were counted. An evaluator blinded of the
treatment assessed all the samples. Positive endometrial cytology was defined as ≥3–5
PMNs per high-power-field.
4.8. Low-Volume Lavage and Multiplex Immunoassay
Low-volume lavage involves infusion of 120 mL of PBS into the uterus, and then the
fluid was retrieved by gentle rectal manipulation of the uterus. The recovered uterine
fluid was placed in two 50 mL tubes and centrifuged at 400× g for 20 min at 5 ◦C, with
the supernatant recovered and centrifuged again at 2000× g for 20 min at 5 ◦C to remove
cellular debris. After the second centrifugation, the supernatant was saved and stored at
−80 ◦C for proteomic analyses.
Uterine fluid interleukins from a subset of mares (n = 6) randomly selected were
analyzed using an equine-specific multiple sandwich immunoassay based on flowmetric
MILLIPLEX MAP® technology in accord with the workflow previously published [64]. The
detection level was defined as the signal-to-noise-ratio (limit of detection) divided by the
square root of 2 (1.6 pg/mL). Data points below the limit of detection were not considered.
Concentration of IL1α, IL1β, IL6, CXCL8, IL17α, IL10, MCP-1, and RANTES in uterine
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fluid obtained by low-volume uterine lavage were measured. Of these, IL-17a, MCP-1, and
RANTES were below the limit of detection for all samples and thus were not considered
further. IL-1α was detected in only two samples with levels only minimally over the limit
of detection and was therefore excluded as well.
Each sample of uterine fluid was measured undiluted, and calibration curves for these
plates were prepared in assay buffer, as previously described by Skogstrand et al. [65]. Ad-
ditionally, samples of interleukins were measured undiluted and standards were prepared
with the serum matrix added to all standards and quality controls, following the guidelines
of the manufacturer and as previously described by Fedorka et al. (2019) [66]. The mean of
intra- assay coefficients of variation weas 3.2%.
4.9. Endometrial Biopsy: Inflammatory Cell Count and Immunolabelling for Progesterone Receptors
Biopsy samples were taken at the cranial uterine body using a sterilized alligator jaw
biopsy forceps. After collection, biopsies were immediately fixed in 10% neutral buffered
formalin and embedded in paraffin for histological evaluation. Tissue was sectioned at 5 µm
thickness and stained with hematoxylin and eosin. For each sample, an evaluator blinded
of treatment counted the number of PMNs and lymphocytes from five randomly selected
high-power fields at 400× magnification. The averages were recorded and compared
across groups.
A subset of mares (n = 4) was used for immunohistochemistry analyses for proges-
terone receptors pre-breeding (−48 h) and eight days post-ovulation (D8, day of embryo
flushing) following manufacturer’s recommendations (Vectastain Standard Elite; Vector
Laboratories, Inc., Burlingame, CA, USA). For immunohistochemistry, tissue sections
(5 µm) were prepared on poly-L-lysine-coated glass slides to detect the presence of proges-
terone receptors (PR). The immunohistochemical staining of all samples was performed
using the avidin–biotin–peroxidase complex procedure with a commercial immunoper-
oxidase kit (Vectastain Standard Elite; Vector Laboratories, Inc., Burlingame, CA, USA).
Tissue sections were immersed in a pre-heated solution at 94 ◦C of Dewax and HIER Buffer
H (Thermo Fischer Scientific, Lab Vision Corporation, Fremont, CA, USA) diluted 1:15
with deionized water for 40 min. This solution is designed to simultaneously dewax and
perform heat-induced epitope retrieval. Endogenous peroxidase was blocked using 1%
hydrogen peroxide in Tris buffer for 45 min. Sections were incubated for 18 h at 4 ◦C with
anti-PR (#MA1-12626, Thermo Fischer Scientific, Lab Vision Corporation, Fremont, CA,
USA) mouse monoclonal antibodies diluted 1:400. After incubation with the secondary
biotinylated anti-mouse immunoglobulin (diluted 1:200; Vector Laboratories, Inc.) for
30 min, the avidin–biotin–peroxidase complex method (Vector Laboratories, Inc.) was
performed. Positive staining was visualized with 3.3-diaminobenzidine-4 HCl (Vectastain,
Vector Laboratories, SK-4100), and nuclei were counterstained with Mayer’s hematoxylin.
Diluent negative control sections were produced by the omission of the primary antibody.
Slides were evaluated by a blinded operator at 200× magnification using a microscope
(OLYMPUS BX51, Olympus, Tokyo, Japan) coupled with a camera and the software ProgRes
C14 PLUS (Jenoptik, Jena, Germany). Five randomly selected areas were evaluated in each
section. The percent and the intensity of PR immunoreactivity (brown stained) cells were
assessed separately in the surface epithelial cells, glandular epithelium, and stroma. The
intensity was scored as 1, weak positive staining; 2, moderate positive staining; and 3,
intense positive staining.
4.10. Progesterone Assay
Plasma samples were collected from the jugular vein once a preovulatory follicle
was detected (D3; ≥33 mm in the presence of endometrial edema), and 48 h (D2) and
eight days after ovulation (D8) for determination of plasma progesterone concentrations.
The concentrations of progesterone were assessed with a chemiluminescence platform
(Immulite 1000 Siemens Medical Solution USA, Inc.). The intra-assay coefficient of variation
was 2.6%, and sensitivity was 0.1 ng/mL.
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4.11. Statistical Analyses
Data analyses were carried out with GraphPad Prism 8.0.1. (GraphPad Software,
San Diego, CA, USA). Luminex data were log (log10) transformed for normalization.
Data were evaluated with a mixed model and Tukey’s post hoc test. The percentage of
embryo flushes with at least one embryo, the number of embryos per ovulations, and the
number of positive bacterial cultures were assessed using multivariate regression analysis.
Significance was set at p ≤ 0.05 for all tests, and a statistically significant tendency was
determined with 0.05 < p < 0.1. All data are presented as mean ± SEM. The degree of linear
correlation between PMNs counting in endometrial cytology and biopsy, as well as platelet
concentration in the whole blood and the PRP, was tested using Pearson correlation. A
strong coefficient of correlation was defined as r > 0.7, moderate as 0.5 ≤ r ≤ 0.7, and a
weak correlation when r < 0.5.
5. Conclusions
In conclusion, the current study suggests that PRP may have antimicrobial properties,
and intrauterine infusion of PRP reduce the chances of uterine infection after breeding in
mares as indicated by the absence of positive bacterial culture in PRP-assigned cycles. In
addition, the intrauterine treatment with blood plasma therapy (rich or poor in platelets)
mitigates the post-breeding uterine inflammatory response of embryo donor mares suscep-
tible to PBIE. The apparent improved immune response is likely one of the major factors
contributing to enhancing embryonic survival and consequent greater embryonic recovery
obtained herein. Administration of blood plasma as prepared herein improved plasma
progesterone concentrations in mares susceptible to PBIE. Finally, as described herein,
plasma infusions can be used as an alternative method to manage embryo donor mares
susceptible to PBIE, and PRP may augment antibiotic therapy in broodmare’s practice.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/antibiotics10050490/s1, Figure S1: The post-breeding inflammatory response in mares after
the sperm challenging. Mares were categorized as susceptible (n = 12) and resistant (n = 7) to
persistent-breeding induced endometritis (PBIE) immediately pre-(0 h) and post-sperm challenging
(24–96 h). (A) Intrauterine fluid accumulation measured at the uterine bifurcation; (B) Mean PMNs
counted in endometrial cytology in five high-power fields (hpf). Different superscripts denote the
effects of time (a,b,c) and differences between mares within each time point (X,Y) (p < 0.05). Figure S2:
Endometrial edema score (median) in mares after the sperm challenging. Mares were categorized
as susceptible (n = 12) and resistant (n = 7) to persistent-breeding induced endometritis (PBIE)
immediately pre-(0 h) and post-sperm challenging (24–96 h). Score 0, No edema; 1, Mild edema;
2, Moderate edema; 3, Evident edema; 4, Exacerbated edema. Different superscripts denote the effects
of time (A,B) (p < 0.05). Figure S3: Circulating progesterone concentrations pre- and post-ovulation in
mares susceptible to persistent breeding-induced endometritis with a positive (Embryo) or negative
(N-Embryo) embryo flushing at eight days post-ovulation. Assessments were carried out from the
early onset of estrus (D-3), 48 h post-ovulation (D2) and on the day of embryo flushing, eight days
post-ovulation (D8). Table S1: Semen parameters for the breeding doses used for breeding mares
assigned to (Control), platelet-rich (PRP), or -poor plasma (PPP). All ejaculates (n = 26) were obtained
from a single fertile stallion.
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